Sabin Vaccine Institute

Promising results have been published from the first human trial testing an experimental vaccine targeting the deadly Marburg virus. Flagged as a potential pandemic-causing virus, this is the first Marburg vaccine to move into Phase 2 human trials.

A clinical trial of a permanent vaccine developed by the US-based Sabin Vaccine Institute for hookworm has been completed in Brazil, giving hope for a permanent end to a problem that affects 600 million people worldwide.